NTRK GENE FUSIONS | Clinical

Brose and Laetsch Discuss Rare Actionable Targets in Patients With Thyroid Cancer

January 12, 2023

During a Targeted Oncology case-based roundtable event, Marcia S. Brose, MD, PhD, and Theodore W. Laetsch, MD, discussed the data supporting the use of NTRK inhibitors in a patient with metastatic papillary thyroid cancer.

Examining NTRK Gene Fusions in Thyroid Cancer

November 28, 2022

Marcia S. Brose, MD, PhD, FASCO, discusses NTRK gene fusions and identifying patients with thyroid cancer.

Clinical Commentary: Testing and Targeting for NTRK Fusions in Non–Small Cell Lung Cancer

October 10, 2022

Mark A. Socinski, MD provides insight on biomarker testing to identify patients with NTRK gene fusion-positive non–small cell lung cancer.

Testing for NTRK Gene Fusions in the Community Setting

September 21, 2022

Alexander Drilon, MD, discusses what community oncologists should know about testing for  NTRK gene fusions in patients with solid tumors.

FDA Clears Phase 1/2 Study of ABT-101 in Non–Small Cell Lung Cancer

September 14, 2022

The FDA has granted approval for an investigational new drug protocol amendment for ABT-101, a mutant selective tyrosine kinase inhibitor which has shown superior selectivity against HER2 exon 20 mutations in NSCLC in preclinical studies.

Looking at the Future of Larotrectinib in NTRK Fusion+ Lung Cancer

September 14, 2022

David S. Hong, MD, discusses what he sees for the future of the NTRK inhibitor larotrectinib.

Larotrectinib Demonstrates Robust Responses in TRK Fusion-Positive Lung Cancer

September 06, 2022

In an interview with Targeted Oncologyy, David S. Hong, MD, discussed an updated analysis of larotrectinib and the data supporting the agent for the treatment of TRK fusion-positive lung tumors.

Choosing Larotrectinib vs Entrectinib to Treat NTRK Fusion+ Lung Cancer

September 04, 2022

David Hong, MD, explains why larotrectinib may be chosen over other TRK inhibitors for the treatment of NTRK fusion-positive lung cancer.

FDA-Approved and Investigational TRK Inhibitors

June 22, 2022

Alexander Drilon, MD, discusses targeted therapies for the patients with NTRK gene fusion-positive cancers.

Real-World Data Show Survival Benefit With Larotrectinib vs Standard of Care in TRK Fusion–Positive Tumors

June 07, 2022

At the 2022 ASCO Annual Meeting, utilizing matching-adjusted indirect comparison, researchers showed the survival benefit of larotrectinib in patients with TRK fusion-positive tumors.